It was approved by the China Food and Drug Administration (CFDA) in June 2020 for first-line treatment of advanced non-squamous NSCLC patients in China who are ineligible for chemotherapy and lack epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations (5). Here, ALK is linked to non-small cell lung carcinoma.